In 2012 and early 2013 we were engaged by CoStim Pharmaceuticals founder Robert Millman and CSO Walter Blattner to help work through a large portfolio of potential immunotherapeutic targets. We vetted each, reviewed the competitive landscape, and drew up preclinical development plans for the lead programs. The company obtained funding from MPM Capital and Atlas Ventures. Today, CoStim was purchased in its entirety by Novartis.
We are proud of the significant role we played in getting CoStim off the ground, and offer the CoStim team and their investors our congratulations for a job well done. Great ideas, great science, great execution.